Konrad Stawiski

Konrad Stawiski is an oncologist, radiation therapist, and bioinformatics scientist specializing in implementing artificial intelligence solutions in oncology. He completed his medical studies at the Medical University of Łódź in 2016 and, since the same year, has been a doctoral student and a researcher at the Department of Biostatistics and Translational Medicine at the Medical University of Łódź. In 2021, he obtained a Ph.D. in medical sciences, and in 2023, he earned the title of a specialist in oncological radiotherapy. Konrad Stawiski is the author and co-author of over 40 English-language articles published in prestigious foreign journals, such as Nature Communications, European Urology Oncology, and eLife. According to Google Scholar, his h-index is 13. Konrad Stawiski is also the recipient of numerous scholarships and awards, including the Minister of Health Award and the Ministry of Science and Higher Education Scholarship. He has led research projects under programs such as Future Generation, NCN Preludium, and currently serves as one of the main researchers in the international ERA PerMed consortium. Konrad Stawiski closely collaborates with doctors and scientists from Dana-Farber Cancer Institute/Harvard Medical School and Broad Institute of MIT and Harvard, where he also completed a foreign scientific internship.

Among Konrad Stawiski's achievements is a patent for a diagnostic test for ovarian cancer based on circulating miRNA, currently undergoing commercialization trials by Aspira Women's Health. He combines specialized clinical knowledge with technological skills, actively programming in R, Python, and C# .NET. More about Konrad Stawiski's profile can be found in his CV at https://konsta.com.pl.